Device Trial Radar · NCT05799950
A Real-World Evidence (RWE) Long-Term Follow-Up Study to Assess Outcomes of Alcon Monofocal Intraocular Lenses
Last checked: Nov 20, 2026Latest source record: Aug 14, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
138
Actual
Start
Aug 28, 2023
Primary completion
Jun 2, 2025
Study completion Jun 2, 2025
Sponsor
- Lead sponsor
- Alcon ResearchNot on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 5, 2023
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes
Summary
As written by the sponsor on the registry.
The purpose of this post-market clinical follow-up (PMCF) study is to describe the long-term safety and performance of AcrySof Single-Piece and AcrySof Multi-Piece monofocal intraocular lenses (IOLs).
Conditions
- Aphakia
Interventions
AcrySof single-piece IOLDevice
Acrylic single-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
AcrySof multi-piece IOLDevice
Acrylic multi-piece intraocular lens placed in the capsular bag in the posterior chamber of the eye during cataract surgery as a replacement for the natural crystalline lens.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean monocular best corrected distance visual acuity (BCDVA)Time frame: Up to 3 to 5 years post operative
- Rate of protocol-specified ocular adverse eventsTime frame: Up to 3 to 5 years post operative
Locations
7 sites in 2 countries. Site status is shown where the registry gives one.
Velvet Clinical Research
Burbank, California
Levenson Eye Associates
Jacksonville, Florida
Virdi Eye Clinic
Rock Island, Illinois
4 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.